Publish Your Research Online
Get Recognition - International Audience
Request for an Author Account | Login | Submit Article
|HOME||FAQ||TOP AUTHORS||FORUMS||PUBLISH ARTICLE|
International Stem Cell Corporation Announces the Commercial Launch of New Skin Care ProductsBY: Pamela Saunders | Category: Press-Release | Submitted: 2010-11-16 13:06:35
Article Summary: "International Stem Cell Corporation Announces the Commercial Launch of Its Breakthrough Stem Cell-Based Line of Skin Care Products.."
International Stem Cell Corporation (OTCBB:ISCO) announced today the commercial launch of its innovative line of topical skin care products by the company's wholly-owned subsidiary, Lifeline Skin Care ™ . Containing extracts from human "parthenogenetic" stem cells (hpSC), the products were formulated by a team of ISCO's research scientists in collaboration with cosmetic formulation experts to create an advanced scientific approach to skin care. The patent pending serums, which come in separate formulations for day and night time use, have been safety tested by highly regarded, independent laboratories, and have been shown to promote anti-aging of the skin.
The initial launch of the serums is to a pre-existing list of interested parties. We expect that the products will be available to the general public via our online store www.lifelineskincare.com in the near future.
A key innovation in creating the Lifeline Skin Care™ serums was the encapsulation of the parthenogenetic stem cell extracts into nanospheres, which not only protect the proteins, but substantially enhance the effectiveness of the serums. World renowned skin cream formulation experts assisted ISCO's scientists to create the finished products and ensure that the final serums deliver the most up-to-date advances in skin rejuvenation technology that also helps to prevent and repair damage caused by the environment.
According to Gregory S. Keller, MD, FACS (2007 Specialist of the Year in Facial Cosmetic Surgery in Strathmore's "Who's Who"): "These new day and night serums represent a huge step forward in anti-aging skin care products. Combining liposome-encapsulated proteins derived from ISCO's powerful new class human stem cells with a unique blend of anti-oxidants, vitamins and natural extracts, allowed Lifeline Skin Care to create highly effective stem cell-based serums that provide strong anti-aging benefits."
The new skin rejuvenation serums are based on the breakthrough discovery that certain proteins derived from ISCO's proprietary pluripotent human parthenogenetic stem cells are beneficial to the culture of human skin cells in the laboratory. ISCO, the world leader in human parthenogenetic stem cell technology, is studying this new class of stem cells, and has demonstrated their therapeutic potential in many fields of regenerative medicine. Human parthenogenetic stem cells are created from unfertilized human eggs and do not involve any harm to a viable human embryo, thus avoiding serious ethical questions that surround other areas of stem cell research. hpSC possess unique immune-matching attributes making them an excellent platform for the development of cellular therapies for large populations of individuals. As of today, ISCO has successfully derived ten hpSC lines. One of these lines carries the most common immune type found within the US population and can be immune-matched to an estimated 75 million people worldwide.
"The commercial launch of the new skin care products represents an important step in the execution of ISCO's strategy. The revenue generated from sales will help support the development of our therapeutic programs utilizing our unique and powerful class of human pluripotent stem cells," said Dr. Ruslan Semechkin, CEO of Lifeline Skin Care.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)
International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and is developing a line of cosmeceutical products via its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website.
Statements pertaining to anticipated developments, product introduction plans, the potential benefits of planned products, collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Key Words: Stem cells, parthenogenesis, biotechnology, skin care, anti-aging
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
Lifeline Skin Care, Inc.
Ruslan Semechkin, PhD, President & CEO
Vice President, ISCO
About Author / Additional Info:
The answers are already there. We are just discovering them - http://intlstemcell.blogspot.com and http://www.lifelineskincare.com
Comments on this article: (0 comments so far)
• Rhizobium - Special Bacteria For Legumes
• Why Should You Go For a PhD in Bioinformatics?
• Jatropha - Control Greenhouse Gas Emissions and Reduce the Oil Import
• Virtual Screening- a Promising Approach to Drug Discovery
Latest Articles in "Press-Release" category:
• Publish Your Biotechnology Press Releases on BiotechArticles.com
• Ginger Technology (Cures for all diseases)
• Greiner Bio-One in Monroe, NC Opens New Warehouse Facility
• MMS Hosts 2011 Scientific Symposium
• Treatment of Domestic Waste Water Using Natural Horse and Cow Dung
• Genotypic and NIPGR Launch Chickpea Gene Expression Microarray
• Low Fat Diet to Reduce Risk of Breast Cancer.
• Epigentek Introduces a Cost-Effective and Reliable Means to Validate Antibodies for ChIP
Important Disclaimer: All articles on this website are for general information only and is not a professional or experts advice. We do not own any responsibility for correctness or authenticity of the information presented in this article, or any loss or injury resulting from it. We do not endorse these articles, we are neither affiliated with the authors of these articles nor responsible for their content. Please see our disclaimer section for complete terms.
Copyright © 2010 biotecharticles.com - Do not copy articles from this website.
ARTICLE CATEGORIES :
| Disclaimer/Privacy/TOS | Submission Guidelines | Contact Us